Fig. 3: YTHDF2 enhances the degradation of EGR1 mRNA in an m6A-dependent manner.
A The Venn plot showed 388 overlapped genes between significantly downregulated genes in MM from GSE47552 and potential RNA targets of YTHDF2 from POSTAR database. B The enrichment analysis was conducted by Metascape. C–F The expression of EGR1 in the development of MM: NPC, MGUS, SMM, MM (C); PCL (D); ISS stage (E) and relapsed MM patients (F). G Kaplan-Meier survival analysis showing the OS for MM patients having low EGR1 expression (blue) and high EGR1 expression (red) in the GSE24080 dataset. H The expression of EGR1 in MM cell lines and normal plasm cells. I, J The mRNA and protein levels of EGR1 upon YTHDF2 knockdown in MM cell lines RPMI-8226 and NCI-H929. K RNA immunoprecipitation assays of EGR1 transcripts in YTHDF2-bound mRNAs in RPMI-8226 and NCI-H929 cells. L RNA stability analysis of EGR1 after actinomycin D treatment in RPMI-8226 cells transfected with siNC and siYTHDF2. M The putative m6A sites of EGR1 mRNA were predicted by POSTAR3. N Methylated RNA immunoprecipitation of EGR1 transcripts in RPMI-8226 and NCI-H929 transfected with siNC and siYTHDF2. Data are mean ± SD values. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. not significant.
